Fenwick & West represented Almirall, S.A. (ALM) in its agreement with 23andMe.
Almirall and 23andMe have signed an agreement allowing Almirall to in-license 23andMe’s bispecific monoclonal antibody designed to block all three members of the IL-36 cytokine subfamily. IL-36 is a part of the IL-1 cytokine family, which is associated with multiple inflammatory diseases, including various dermatological conditions. Almirall will secure the rights to develop and commercialize the antibody for worldwide use. This agreement will strengthen Almirall’s early-stage research portfolio.
Headquarters in Barcelona, Almirall is a leading skin-health focused global pharmaceutical company that partners with healthcare professionals, applying science to provide medical solutions to patients and future generations.
23andMe, Inc. is the leading consumer genetics and research company. Founded in 2006, the mission of the company is to help people access, understand and benefit from the human genome.
The Fenwick transaction team was led by intellectual property counsel Claire O’Callaghan (Picture).
Involved fees earner: Claire O’Callaghan – Fenwick & West LLP;
Law Firms: Fenwick & West LLP;
Clients: Almirall S.A.;